Last reviewed · How we verify
NCT05779163
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
Phase 1, PHASE2 trial testing LBL-033 for Injection in Advanced Malignant Tumors in 468 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Nanjing Leads Biolabs Co.,Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 468 |
| Start date | 14 April 2023 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 6 locations across China |
Drugs / interventions tested
- LBL-033 for Injection — full drug profile →
Conditions studied
- Advanced Malignant Tumors — all drugs for Advanced Malignant Tumors →
Sponsor
Nanjing Leads Biolabs Co.,Ltd — full company profile →
Who can join
18 and older, any sex, with Advanced Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current landscape of T-cell engagers in early-phase clinical development in solid cancers.
Spinazzola A, Iannantuono GM, Gulley JL, Giudice E, et al · · 2025 · cited 3× · PMID 41122165 · DOI 10.3389/fimmu.2025.1665838
Verify or expand the search:
- PubMed search for NCT05779163
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Malignant Tumors
Currently open trials in the same condition.
- NCT07038005 — A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT07016490 — A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT06877650 — First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
- NCT06764771 — A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors · Phase 1 · active not recruiting
- NCT06223841 — A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
Other Nanjing Leads Biolabs Co.,Ltd trials
Trials by the same sponsor.
- NCT07390383 — A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] · Phase 2 · not yet recruiting
- NCT07331155 — A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] · Phase 2 · recruiting
- NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT07323173 — A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus · Phase 1 · recruiting
- NCT07042802 — A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05779163 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing Leads Biolabs Co.,Ltd
- Last refreshed: 7 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05779163.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing